Mauna Kea Technologies SAS - Asset Resilience Ratio
Mauna Kea Technologies SAS (ALMKT) has an Asset Resilience Ratio of 5.24% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check ALMKT PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2024)
This chart shows how Mauna Kea Technologies SAS's Asset Resilience Ratio has changed over time. See debt-free asset ratio of Mauna Kea Technologies SAS to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Mauna Kea Technologies SAS's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Mauna Kea Technologies SAS worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €663.00K | 5.24% |
| Short-term Investments | €0.00 | 0% |
| Total Liquid Assets | €663.00K | 5.24% |
Asset Resilience Insights
- Limited Liquidity: Mauna Kea Technologies SAS maintains only 5.24% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Mauna Kea Technologies SAS Industry Peers by Asset Resilience Ratio
Compare Mauna Kea Technologies SAS's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
Inspire Medical Systems Inc
NYSE:INSP |
Medical Devices | 20.29% |
|
Shanghai General Healthy Information and Technology Co. Ltd.
SHG:605186 |
Medical Devices | 0.84% |
|
Medprin Regenerative Medical Technologies Co. Ltd.
SHE:301033 |
Medical Devices | 19.31% |
|
Stratec SE
XETRA:SBS |
Medical Devices | 0.30% |
|
Duearity AB
ST:DEAR |
Medical Devices | 145.62% |
|
Anteris Technologies Global Corp
AU:AVR |
Medical Devices | 33.27% |
|
Polynovo Ltd
AU:PNV |
Medical Devices | 0.04% |
Annual Asset Resilience Ratio for Mauna Kea Technologies SAS (2011–2024)
The table below shows the annual Asset Resilience Ratio data for Mauna Kea Technologies SAS.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 12.42% | €2.02 Million ≈ $2.36 Million |
€16.25 Million ≈ $18.99 Million |
+12.26pp |
| 2023-12-31 | 0.16% | €36.00K ≈ $42.09K |
€22.94 Million ≈ $26.82 Million |
+0.11pp |
| 2022-12-31 | 0.05% | €9.00K ≈ $10.52K |
€19.79 Million ≈ $23.14 Million |
-0.07pp |
| 2021-12-31 | 0.12% | €29.00K ≈ $33.90K |
€24.75 Million ≈ $28.94 Million |
-0.16pp |
| 2020-12-31 | 0.28% | €58.00K ≈ $67.81K |
€20.61 Million ≈ $24.09 Million |
+0.03pp |
| 2019-12-31 | 0.25% | €59.00K ≈ $68.98K |
€23.62 Million ≈ $27.62 Million |
-0.07pp |
| 2018-12-31 | 0.32% | €64.00K ≈ $74.82K |
€19.76 Million ≈ $23.10 Million |
-0.13pp |
| 2017-12-31 | 0.45% | €125.00K ≈ $146.14K |
€27.75 Million ≈ $32.44 Million |
-0.02pp |
| 2016-12-31 | 0.47% | €94.00K ≈ $109.90K |
€19.97 Million ≈ $23.35 Million |
+0.18pp |
| 2015-12-31 | 0.29% | €65.00K ≈ $75.99K |
€22.50 Million ≈ $26.31 Million |
-0.18pp |
| 2014-12-31 | 0.46% | €128.00K ≈ $149.65K |
€27.54 Million ≈ $32.19 Million |
-0.06pp |
| 2013-12-31 | 0.52% | €207.00K ≈ $242.00K |
€39.54 Million ≈ $46.23 Million |
+0.09pp |
| 2012-12-31 | 0.43% | €211.00K ≈ $246.68K |
€49.06 Million ≈ $57.35 Million |
-1.13pp |
| 2011-12-31 | 1.56% | €943.00K ≈ $1.10 Million |
€60.30 Million ≈ $70.50 Million |
-- |
About Mauna Kea Technologies SAS
Mauna Kea Technologies SA manufactures and sells medical devices in Europe and internationally. It offers a range of medical devices for gastroenterology, pulmonology, and urology applications. Its product portfolio includes Cellvizio, a real-time in vivo cellular imaging platform that enables unique in vivo cellular visualization, allowing doctors to monitor disease evolution over time, evaluate… Read more